We herewith enclose the Audited Financial Results of the Company along with the Statutory Auditor''s Report for the Quarter and Year ended March 31, 2026, as approved by the Board of Directors ....
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bafna Pharmaceuticals reported annual revenue of ₹15,061.74 lakhs for FY26, up 3.3% from ₹14,585.70 lakhs in FY25. Profit before tax (before exceptional items) surged to ₹1,097.02 lakhs from ₹415.25 lakhs in the prior year, while PAT jumped over 6x to ₹1,099.98 lakhs from ₹153.55 lakhs. EBITDA margin expanded significantly from ~6.2% to ~11%. The statutory auditor issued an unmodified opinion but included an Emphasis of Matter regarding GST demands — a demand of ₹235.47 lakhs and recovery of GST refunds of ₹331.09 lakhs with interest and penalty, against which the company has filed appeals. Exceptional items of ₹178.87 lakhs (derecognition of inventory and intangible assets) were recorded. Borrowings increased, pushing debt-to-equity from 0.33 to 0.39.
Strong profit growth and margin expansion are positives, but GST-related contingent liabilities of ₹566.56 lakhs and rising debt levels warrant monitoring. The unmodified audit opinion provides assurance on financial statement reliability.